Lung cancer highlights from WCLC and ESMO 2024

Lung cancer highlights from WCLC and ESMO 2024

Dr Herbert H. Loong shares his views on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at the WCLC and ESMO 2024 congresses.

 

Dr Loong reviews data and provides his key clinical takeaways from the studies below. 

 

 

Clinical takeaways

 

ROS1

  • TRUST-II: Taletrectinib demonstrated high and durable overall responses, robust IC activity in TKI-naïve and TKI-pretreated patients with ROS1+ NSCLC, and is a potential new therapy for this patient population. Data from TRUST-II supports the efficacy and safety of taletrectinib across regions and ethnicities [Liu G, et al. Abstract MA06.03, WCLC 2024]

KRAS

  • LOXO-RAS-20001: demonstrates the feasibility of combining KRAS G12C inhibitors with chemotherapy and immunotherapy. Preliminary efficacy was demonstrated with an ORR of 50% in a higher risk (PD-L1 low/negative) population. Olomorasib combined with chemo-immunotherapy demonstrated a manageable safety profile [Fujiwara Y, et al. Abstract OA14.04, WCLC 2024]

HER2 mutations

  • SOHO-01: Treatment with BAY 2927088 led to rapid, substantial, and durable responses in patients with heavily pretreated HER2-mutant NSCLC. The safety profile of BAY 2927088 was manageable and consistent with previous reports [Le X, et al. Abstract PL04.03, WCLC 2024]
  • Beamion LUNG-1: Zongertinib demonstrated significant and clinically meaningful activity in patients with pre-treated NSCLC with a HER2 TKD mutation, including in those with brain metastases and was well tolerated [Ruiter G, et al. Abstract PL04.04, WCLC 2024]

HER2 Over expression

  • DESTINY-Lung03: T-DXd monotherapy demonstrated encouraging antitumor activity in patients with pretreated advanced or metastatic HER2-OE NSCLC, and had an acceptable safety profile, consistent with the known profile of T-DXd [Planchard D, et al. Abstract OA16.05, WCLC 2024]

ALK

  • ALKOVE-1: NVL-655 was well-tolerated and the emerging safety profile was consistent with ALK-selective, TRK-sparing design. Durable responses were observed in a heavily pre-treated population and across patient subgroups [Drilon A, et al. Abstract 1253O, ESMO 2024]

EGFR

  • MARIPOSA: Amivantamab plus lazertinib had significantly reduced the incidence of MET amplifications and EGFR resistance alterations versus osimertinib [Besse B, et al. Abstract LBA55, ESMO 2024]

 

Watch the short video update and download the accompanying slides to see the key data from these trials. 

  • Understand the clinical trial data and emerging profile of targeted therapies for the treatment of molecularly driven lung cancer 

Dr Herbert H. Loong holds conjoint appointments of Clinical Associate Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase 1 Clinical Trials Centre of The Chinese University of Hong Kong.

 

Dr Loong obtained his medical degree with a Distinction in Surgery from The University of Hong Kong in 2003. He has completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a focus on Experimental Therapeutics. His clinical and research interests include Thoracic Oncology, Sarcoma Medical Oncology and Health Economics.

 

Dr Loong is a recipient of the European Cancer Congress Fellowship Grant (2013), the American Society of Clinical Oncology (ASCO) Annual Meeting Merit Award (2014), the Hong Kong College of Physicians Young Investigators’ Award (2014). Dr. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018.

 

In recent years, Dr Loong has co-founded the Asia Pacific Oncology Drug Development Consortium (APODDC) and the Asia Pacific Coalition Against Lung Cancer (APCLC).

 

Dr Loong has served or continues to serve in various capacities in various professional international oncology bodies, including the International Affairs Committee and the Asia-Pacific Regional Council of ASCO, the Membership, Education and Communications Committees of the IASLC. He is the incoming Chairman of the International Affairs Committee of ASCO in 2024. He has been elected as a Board Member of the Connective Tissue Oncology Society (CTOS) for 2022-2024. In his prior appointment as a member of Pharmacy and Poisons Board of Hong Kong, he oversaw the registration of medicinal products and clinical trials in the territory.

Dr Herbert H. Loong has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AbbVie, Amgen, Bayer, Boehringer-Ingelheim, Celgene, Eisai, Eli-Lilly, George Clinical, Guardant Health, Illumina, Janssen, Novartis, Merck Sereno, Pfizer, Takeda

Prof. David Planchard and Dr Federico Cappuzzo share their views on the latest data on BRAF-altered non-small cell lung cancer (NSCLC) presented at the ESMO 2024 congress.   

 

Watch and listen as the experts reveal what they consider to be the key takeaways that HCPs need to know.

 

Clinical takeaways

  • PHAROS: Long-term follow up of ~ 32 months from the PHAROS study showed that encorafenib plus binimetinib continued to show substantial antitumour activity in treatment-naïve BRAF-V600E mutant mNSCLC patients. The safety profile of the combination remained consistent with the earlier analysis [Riely G, et al. Abstract LBA56, ESMO 2024]
  • IFCT-1904 ENCO-BRAF: French study which showed antitumour activity in treatment-naïve BRAF V600E-mutant advanced NSCLC patients treated with encorafenib plus binimetinib. The safety profile was manageable and consistent with previous reports in NSCLC and melanoma [Planchard D, et al. Abstract 1259MO, ESMO 2024]
    • The results of the PHAROS and IFCT-1904 ENCO-BRAF trials confirm the validity of targeting BRAF and MEK in BRAF V600E-mutant non-small cell lung cancer
  • 1L IO vs BRAF and MEK inhibitors: A retrospective study which looked at clinicopathologic and outcomes data from patients with mNSCLC who received first-line treatment with either an ICI ±CT or a BRAFi + MEKi. Outcomes varied by line of treatment, smoking pack years and PD-L1 status, suggesting clinical factors should be used to tailor first-line therapy in these patients [Di Federico A, et al. Abstract 1299P, ESMO 2024]
  • MoST: First line treatment with vemurafenib plus cobimetinib resulted in significant clinical antitumour activity in treatment naïve BRAF V600E-mutated NSCLC [Lin F, et al. Abstract 623P, ESMO 2024]

 

Watch the short video update to hear more about the key data from BRAF-altered lung cancer trials. 

 

This content is intended for HCPs outside the UK and ROI only.

  • Understand the latest highlights on BRAF-altered NSCLC data from the ESMO 2024 conference  

Dr. Federico Cappuzzo is the Director of Medical Oncology at the National Cancer Institute Regina Elena in Rome.

In November 1992, he graduated with highest honours in Medicine and surgery at the Palermo University and in November 1996, yielded a Degree with highest honours in Medical Oncology at Milan University, followed by the ESMO (European Society for Medical Oncology) certification in Medical Oncology in 1997.

From 1997 to 1999 he was recipient of an ESMO Fellowship on Gene Therapy of Lung Cancer at Institut Gustave Roussy in Villejuif (Paris). Followed by attendance from April 2000 to September 2000 at the thoracic oncology unit at Medical University of South Carolina in Charleston (USA).

For six years, from November 2000 to 2006, he was assistant professor at Ospedale Bellaria in Bologna and from November 2006 to January 2010 he was assistant professor in Medical Oncology at Istituto Clinico Humanitas IRCCS in Rozzano (Milano), which was followed in January 2004 to November 2004 as visiting professor in Medical Oncology at University of Colorado in Denver (USA).

From January 2010 to April 2016 he was the Director of Medical Oncology Department at the Istituto Toscano Tumori-Ospedale Civile in Livorno. From April 2016 to September 2020 he was Director of Oncology and Hematology Department at AUSL Romagna in Ravenna.

Dr. Cappuzzo is a member of the Italian Association in Medical Oncology (AIOM), European

Society for Medical Oncology (ESMO), American Society Clinical Oncology (ASCO) and

International Association for the Study of Lung Cancer (IASCL) and since 2006 as a Memberof the editorial board of Lung Cancer. From 2013 to 2017 he was the Chairman of the Educational Committee of IASLC. He is the author of more than 250 papers in peer-review journals, mainly in translational research in lung cancer.

Dr Federico Cappuzzo has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, AstraZeneca, Bayer, Beigene, BMS, Galecto, ILLUMINA, Lilly, OSE, Mirati, MSD, Novocure, Pharmamar, Pfizer, Roche, Thermofisher, Sanofi, Takeda

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Programme summary
  • clock Duration 8 MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4

HCC highlights from ESMO 2024

Dr Richard Finn shares his views on the latest HCC data on immunotherapy (IO) and IO-based treatments presented at the ESMO 2024 congress.  

 

Dr Finn reviews data and provides clinical takeaways from the studies below.

 

Clinical takeaways

 

  • HIMALAYA: Results from the extended follow-up set a new benchmark in unresectable HCC, with one in five patients alive with single tremelimumab regular interval durvalumab (STRIDE) at 5 years [Rimassa L, et al. Abstract 947MO, ESMO2024]
  • CheckMate 9DW: Further supports nivolumab + ipilimumab as a potential first-line treatment option for patients with unresectable HCC [Decaens T, et al. Abstract 965MO, ESMO 2024]
  • LEAP-012: Met its primary endpoint. Lenvatinib + pembrolizumab + TACE showed a statistically significant and clinically meaningful improvement in PFS and an early trend towards improvement in OS versus placebo + TACE in patients with intermediate HCC [Llovet J, et al. Abstract LBA3, ESMO 2024]
  • IMbrave050: Does not support atezolizumab + bevacizumab as an adjuvant therapy for all high-risk HCC [Yopp A, et al. Abstract LBA39, ESMO 2024]

 

Watch the short video update and download the accompanying slides to see the key data from these trials.

 

AstraZeneca has provided a sponsorship grant towards this independent Programme.

Understand the latest practice changing HCC data on IO and IO-based treatments from the conference and how this could be implemented in clinical practice.

Dr Richard Finn is a professor of Medicine at the Geffen School of Medicine at UCLA in the Department of Medicine, Division of Hematology/Oncology. He was an undergraduate at UCLA where he was involved with early laboratory studies investigating the HER2 oncogene and the development of monoclonal antibodies to this target in breast cancer with Dr Dennis Slamon. He participated in the pre-clinical studies that defined the clinical candidate that eventually humanized and became the FDA approved agent trastuzumab (Herceptin). He went on to medical school at USC then returned to UCLA for his clinical training in Internal Medicine and then Hematology/ Oncology. He currently splits his time between patient care and directing the Translational Research Laboratory in the Division of Hematology/Oncology. His research interests are focused in the development of targeted therapeutics for solid tumors across histologies to support the larger efforts of the department. His personal interests lie in the development of these targeted agents in Hepato-biliary and breast cancers. He has two-half days dedicated to patient care, one of which is as a leader in the multi-disciplinary hepato-biliary cancer program at UCLA where he is involved with clinical studies aimed at bringing novel therapeutics into the treatment of patients with these malignancies.

Programme summary
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from AstraZeneca. 
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca. 
Endorsement
I agree that this educational programme:

Was valuable to me

1/4

Breast cancer highlights from ESMO 2024

Prof. François-Clément Bidard shares his views on the latest breast cancer data presented at the ESMO 2024 congress.   

 

Watch as he reveals what he considers to be the key clinical takeaways from the following trials: 

  • Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study [Schmid P, et al. Abstract LBA4, ESMO 2024]
  • Trastuzumab deruxtecan in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: DESTINYBreast-12 primary results [Lin N, et al. Abstract LBA18, ESMO 2024]
  • Adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with HR+/HER2− early breast cancer: 4-year outcomes from the NATALEE Trial [Fasching P, et al. Abstract LBA13, ESMO 2024]

Understand the latest highlights on practice-changing breast cancer data from the ESMO 2024 conference 

François-Clément Bidard, MD PhD, is a Professor of Medical Oncology in Paris and Saint-Cloud, France. His clinical work is dedicated to breast cancer care, whereas his translational and clinical research focuses on all forms of liquid biopsy and new therapies to move ahead of cancer resistance.

Prof. François-Clément Bidard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Prof. Bidart discloses financial support/sponsorship from AstraZeneca, Daiichi-Sankyo, Caris, Exact Sciences, General Electrics Healthcare, GSK, Inatherys, Lilly, Merck KGaA, Menarini Silicon Biosystems, Menarini/Stemline, Novartis, Pfizer, Prolynx, Rain Oncology, Roche, SAGA Diagnostics, Seagen, Sanofi

Programme summary
  • clock Duration 5 MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from COR2ED.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from COR2ED.
I agree that this educational programme:

Was valuable to me

1/4

GU cancer highlights from ESMO 2024

In this short video update, Dr. Ray Manneh Kopp shares his perspective on the latest data presented at the ESMO 2024 congress, covering renal, bladder and prostate cancers.   

 

Watch the video for his summary of the key clinical takeaways from the following trials: 

  • A randomised multicenter open label phase 3 trial comparing enzalutamide vs a combination of Radium-223 and enzalutamide in asymptomatic or mildly symptomatic patients with bone mCRPC: First results of EORTC-GUCG 1333/PEACE-3 [Gillessen S, et al. Abstract LBA1, ESMO 2024]
  • A randomised phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA) [Powles T, et al. Abstract LBA5, ESMO 2024]
  • Tivozanib–nivolumab vs tivozanib monotherapy in patients with RCC following 1 or 2 prior therapies including an immune checkpoint inhibitor – Results of the phase 3 TiNivo-2 Study [Choueiri T, et al. Abstract LBA73, ESMO 2024]
  • Understand the latest highlights on practice-changing GU cancer data from the ESMO 2024 conference  

Scientific director at Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia. Chief of Genitourinary Unit and Clinical Research Unit. Medical Oncologist at Clínica Portoazul, Barranquilla, Colombia. I completed medical school at Universidad del Norte, Barranquilla Colombia.  Medical oncologist from University Hospital 12 de Octubre in Madrid, Genitourinary Fellow in the GU unit at  University Hospital 12 de Octubre. Master in molecular oncology from Centro de estudios biosanitarios, CNIIO, ESO. Founder of Grupo de Oncología Genitourinaria de Colombia.  Member of SEOM, ACHO and LACOG-GU. I focus my practice on patients with prostate, bladder, kidney and testicular cancer. 

Dr Ray Manneh Kopp has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, AstraZeneca, BMS, Dr Reddys, Roche, Janssen, Lilly, MSD, Novartis and Technofarma.

Programme summary
  • clock Duration 4 MIN
  • clock Language(s) flag
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Educational Grant from COR2ED.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from COR2ED.
I agree that this educational programme:

Was valuable to me

1/4

Precision oncology poster presentation

Precision oncology poster presentation

We are pleased to share that PRECISION ONCOLOGY CONNECT presented the results from a non-small cell lung cancer global patient and caregiver survey in a poster at ESMO 2024.

 

Read more about the survey and download the poster: Assessing biomarker testing awareness among patients and caregivers in NSCLC

Programme summary
  • clock Duration 5 MIN
  • clock Language(s) flag
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

conference-update Conference update
Oncology 
ER+ metastatic breast cancer: Highlights from the 13th APBCS Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer  

Experts
Prof. Shaheenah Dawood, Prof. Heather McArthur, Prof. Javier Cortés, Prof. Frédérique Penault-Llorca
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Σειρά podcast για τη διαχείριση της θρόμβωσης

Αναλύσεις από καταξιωμένους ειδικούς ιατρούς. Πλοηγηθείτε στις καρτέλες για να επιλέξετε ένα επεισόδιο podcast

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
ESMO Virtual Plenary: Final OS results from the phase III TROPION-Breast01 trial

How will the latest Dato-DXd data impact treatment strategies for HR+/HER2− mBC?

Experts
Prof. François-Clément Bidard, Dr Barbara Pistilli
  • clock 5 MIN
  • calendar Feb 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca
podcast Podcast
Oncology Obstetrics and Gynecology 
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions

Understanding the role of molecular subtypes in guiding treatment selection

Experts
Prof. Xavier Matias-Guiu, Dr Jurjees Hasan
Endorsed by
Biomarker Collaborative ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 11 MIN
  • calendar Feb 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this Video Podcast.
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Postępowanie w przypadku zakrzepicy – seria podcastów

Uznani eksperci dzielą się swoimi spostrzeżeniami. Kliknij na odpowiednią zakładkę, aby wybrać odcinek podcastu.

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
Highlights from ASCO GI 2025

Expert insights on BRAF-mutated colorectal cancer

Experts
Dr Elena Élez
Endorsed by
DiCE BRAF Bombers ICAN international cancer advocacy network
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025

Educational programme supported by an Independent Educational Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. This content is intended for HCPs outside the UK and ROl only.